6-oxo-N-(1-phenylbutan-2-yl)-5H-benzo[b][1,4]benzothiazepine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 6-oxo-N-(1-phenylbutan-2-yl)-5H-benzo[b][1,4]benzothiazepine-3-carboxamide
• 化学式: C₂₄H₂₂N₂O₂S
• 分子量: 402.5
• InChiKey: AAOMCPIGXHPOEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10265313B2

  公开（公告）日：2019-04-23

  The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2  (I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

  本发明提供了治疗或预防疟疾的方法，包括向动物施用有效量的式 I 化合物： Q-Y-R1-R2 (I)、 其中Q、Y、R1和R2如本文所述。本发明还提供了抑制动物体内寄生虫的质体表面阴离子通道的方法。本发明还提供了药物组合物，其包含式 I 所代表的化合物与式 II、V 和 VI 所代表的任意一种或多种化合物的组合。本发明还提供了药物组合物用于治疗或预防疟疾或抑制动物（包括人类）的质体表面阴离子通道的用途。本发明还提供了 clag3 氨基酸序列和相关核酸、载体、宿主细胞、细胞群、抗体和药物组合物。
• Inhibitors of the plasmodial surface anion channel as antimalarials
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10881669B2

  公开（公告）日：2021-01-05

  Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.

  本发明公开了质体表面阴离子通道（PSAC）抑制剂的抑制剂及其在治疗或预防动物（如人类）疟疾中的用途，包括施用有效量的抑制剂或抑制剂组合。这种抑制剂的一个例子是式 I 的化合物、 或其药学上可接受的盐，其中 R1 至 R7 如本文所述。
• INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS
  申请人：The United States Of America, As Represented By The Secretary, Department Of Health And Human Services

  公开号：EP2313100B1

  公开（公告）日：2016-05-11
• PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA
  申请人：The United States of America, as represented by The Secretary, Department of Health and Human Services

  公开号：EP2696873B1

  公开（公告）日：2022-08-03
• US9394316B2
  申请人：——

  公开号：US9394316B2

  公开（公告）日：2016-07-19